Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236311 | 0.92 | ALDH1A1 (0.54) | TGM2HTTKDM4EALDH1A1KMT2A | |
| SCHEMBL29790025 | 0.84 | ALDH1A1 (0.47) | TGM2HTTALDH1A1KMT2AKEAP1 | |
| SCHEMBL793834 | 0.84 | ALDH1A1 (0.47) | TGM2HTTALDH1A1KMT2AKEAP1 | |
| SCHEMBL11964039 | 0.83 | ALDH1A1 (0.49) | TGM2HTTALDH1A1KMT2AKEAP1 | |
| SCHEMBL4365743 | 0.82 | TGM2 (0.58) | TGM2HTTKEAP1NFE2L2LMNA | |
| SCHEMBL3067744 | 0.82 | HTT (0.67) | TGM2HTTKEAP1NFE2L2LMNA | |
| SCHEMBL4373055 | 0.82 | HTT (0.67) | TGM2HTTKEAP1NFE2L2LMNA | |
| SCHEMBL13876824 | 0.81 | CHRM2 (0.57) | TGM2HTTALDH1A1KEAP1NFE2L2 | |
| SCHEMBL4367462 | 0.81 | BCHE (0.57) | TGM2HTTALDH1A1KEAP1NFE2L2 | |
| SCHEMBL30640871 | 0.81 | HTT (0.55) | TGM2HTTALDH1A1KMT2AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2005-11-24 | — | — | US | disclosed |
| EP-1497257-A1 | 2,5-BIS-DIAMINE-[1,4] BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | Alma Mater Studiorum -Universita' di Bologna (IT) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087035-A1 | 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | PSEN2, BACE2, WEE2 | TGM2 532/4885HTT 714/4885KDM4E 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.